Novo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOMWlFaF9yQXl1azczbExDallSSXZxUGd6aTJXVkw5Y3ZiOWRLdTBVcUo1bDl6TEdXNjBPV0hmNEdfaXRhQkJjVHNHTHVDdmhoSUZUT294T3VGbndYN3dNY3I3SXdJNzN6RDlDYUl2M1RZQW9PdENzRUhjWE1tZVk5ZjduZ04xY0VrX1IxS3duN1Faajk1dDFEdDktT2xxZzBPb1cySlZfRlI2SXJCV2dmR2xjc2U0M3IzSU1LbGZmaw?oc=5" target="_blank">Novo Nordisk to license experimental GLP-1 pill from China's Hengrui</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble - Reuters
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble Reuters
October 8, 2026 at 08:49 PMViatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters
Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters
October 8, 2026 at 02:39 PMPepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies - Reuters
PepsiCo running out of time to meet Elliott-inspired targets as GLP-1 threat intensifies Reuters
October 7, 2026 at 11:36 AMCSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters
October 4, 2026 at 10:18 PMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMDisney licenses lineup of movies, TV shows to Netflix including 'Ice Age,' 'Will Trent' - Reuters
Disney licenses lineup of movies, TV shows to Netflix including 'Ice Age,' 'Will Trent' Reuters
October 2, 2026 at 08:56 PM